It seemed like the perfect plan.
Jason Sheltzer, a cancer biologist at Cold Spring Harbor Laboratory in New York, was on the hunt for genes involved in tumour growth. He and his colleagues planned to disable genes using the popular gene-editing tool CRISPR–Cas9, then look for changes that reduced the rate at which cancer cells multiply. But they needed a control gene that would yield that same effect.